AKBA Q1 2017 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$366M

Q1 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$21M

Gross Profit

-$39M-187.8% margin

Operating Income

-$45M-215.5% margin

Net Income

-$45M-213.5% margin

EPS (Diluted)

$-1.15

QoQ Revenue Growth

+1259.3%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$259M

Total Liabilities

$229M

Stockholders' Equity

$31M

Cash & Equivalents

$87M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$0	—
Gross Profit	-$39M	-$20M	-93.6%
Operating Income	-$45M	-$26M	-72.7%
Net Income	-$45M	-$26M	-72.7%